Tilray Medical Joins Fight Against Deadly Brain Tumors, Here's What's Happening
Portfolio Pulse from Jelena Martinovic
Tilray Medical, a division of Tilray Brands, Inc. (NASDAQ:TLRY) (TSX:TLRY), is contributing to a clinical trial researching the efficacy of medical cannabis as a treatment for glioblastoma, a severe form of brain cancer. The trial will be conducted in Spain and will recruit 30 patients from eight specialized neuro-oncology medical sites. Tilray Medical will provide the pharmaceutical-grade medical cannabis for the trial. The trial commenced on September 5, 2023.
October 16, 2023 | 12:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tilray's involvement in a clinical trial for a potential new treatment for glioblastoma could potentially boost its reputation in the medical cannabis sector. However, the outcome of the trial is uncertain and could impact the company's stock in the future.
Tilray's involvement in this clinical trial could potentially boost its reputation and credibility in the medical cannabis sector, which could positively impact its stock. However, the outcome of the trial is uncertain and could either positively or negatively impact the company's stock in the future.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100